Pasar al contenido principal

GI-1611: Química Biológica y Supramolecular

IJC2019-040358-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Juan de la Cierva Incorporación
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Deactivation of a dimeric DNA-binding peptide through a palladium-mediated self-immolative cleavage

  • Rodríguez, Jéssica
  • Pérez-González, Daniel Cibrán
  • Martínez-Calvo, Miguel
  • Mosquera Mosquera, Jesús
  • Mascareñas, José
[Abstract]: Herein, we describe an approach for the on-demand disassembly of dimeric peptides using a palladium-mediated cleavage of a designed self-immolative linker. The utility of the strategy is demonstrated for the case of dimeric basic regions of bZIP transcription factors. While the dimer binds designed DNA sequences with good affinities, the peptide–DNA complex can be readily dismounted by addition of palladium reagents that trigger the cleavage of the spacer, and the release of unfunctional monomeric peptides., We are thankful for the financial support from the Xunta de Galicia (Centro singular de investigación de Galicia acreditación 2019–2022, ED431G 2019/03) and the European Union (European Regional Development Fund – ERDF). We also thank support given by the Spanish grants PID2019-108624RB-I00, the Xunta de Galicia (grants 2015-CP082, ED431C 2017/19 and 2021-CP054, ED431C-2021/25) and the European Research Council (Advanced Grant No. 340055). MMC and JR thank the MCIN/AEI for their Postdoctoral fellowships (IJCI-2014-19326 and IJC2019-040358-I). Authors would like to thank the use of RIAIDT-USC analytical facilities., Xunta de Galicia; ED431G 2019/03, Xunta de Galicia; 2015-CP082, Xunta de Galicia; ED431C 2017/19, Xunta de Galicia; 2021-CP054, Xunta de Galicia; ED431C-2021/25
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy

  • Alcalá, Sonia
  • Villarino, Lara
  • Ruiz-Cañas, Laura
  • Couceiro, José R.
  • Martínez‑Calvo, Miguel
  • Palencia-Campos, Adrián
  • Navarro, Diego
  • Cabezas-Sainz, Pablo
  • Rodríguez‑Arabaolaza, Iker
  • Cordero‑Barreal, Alfonso
  • Trilla-Fuertes, Lucía
  • Rubiolo, Juan A.
  • Batres-Ramos, Sandra
  • Vallespinós, Mireia
  • González‑Páramos, Cristina
  • Rodríguez, Jéssica
  • Gámez, Ángelo
  • Fresno Vara, Juan Ángel
  • Fra Fernández, Sara
  • Benito Berlinches, Amparo
  • Moreno‑Mata, Nicolás
  • Torres Redondo, Ana María
  • Carrato, Alfredo
  • Hermann, Patrick C.
  • Sánchez, Laura
  • Torrente, Susana
  • Fernández‑Moreno, Miguel Ángel
  • Mascareñas, José L.
  • Sainz, Bruno Jr.
[Background]: Previous studies by our group have shown that oxidative phosphorylation (OXPHOS) is the main pathway by which pancreatic cancer stem cells (CSCs) meet their energetic requirements; therefore, OXPHOS represents an Achille’s heel of these highly tumorigenic cells. Unfortunately, therapies that target OXPHOS in CSCs are lacking., [Methods]: The safety and anti-CSC activity of a ruthenium complex featuring bipyridine and terpyridine ligands and one coordination labile position (Ru1) were evaluated across primary pancreatic cancer cultures and in vivo, using 8 patient-derived xenografts (PDXs). RNAseq analysis followed by mitochondria-specific molecular assays were used to determine the mechanism of action., [Results]: We show that Ru1 is capable of inhibiting CSC OXPHOS function in vitro, and more importantly, it presents excellent anti-cancer activity, with low toxicity, across a large panel of human pancreatic PDXs, as well as in colorectal cancer and osteosarcoma PDXs. Mechanistic studies suggest that this activity stems from Ru1 binding to the D-loop region of the mitochondrial DNA of CSCs, inhibiting OXPHOS complex-associated transcription, leading to reduced mitochondrial oxygen consumption, membrane potential, and ATP production, all of which are necessary for CSCs, which heavily depend on mitochondrial respiration., [Conclusions]: Overall, the coordination complex Ru1 represents not only an exciting new anti-cancer agent, but also a molecular tool to dissect the role of OXPHOS in CSCs. Results indicating that the compound is safe, non-toxic and highly effective in vivo are extremely exciting, and have allowed us to uncover unprecedented mechanistic possibilities to fight different cancer types based on targeting CSC OXPHOS., This study was supported by a Fero Foundation Grant (B.S.,Jr.); Rámon y Cajal Merit Award (RYC-2012-12104) from the Ministerio de Economía y Competitividad, Spain (B.S.,Jr.); funding from the Beca Carmen Delgado/Miguel Pérez-Mateo from AESPANC-ACANPAN Spain (B.S.,Jr.); a Conquer Cancer Now Grant from the Concern Foundation (Los Angeles, CA, USA) (B.S.,Jr.); a Coordinated grant (GC16173694BARB; B.S.,Jr.) and SEED grant (IDEAS222917FERN; M.A.F.-M.) from the Fundación Asociación Española Contra el Cáncer (AECC); FIS grants PI18/00757 and PI21/01110 (B.S.,Jr.) and PT20/00045 (A.M.T.R and B.S.,Jr.), (co-financed through Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa”); an IGNICIA proof of concept grant (IN855A-2018/16) “RuCSC - targeting cancer stem cells using ruthenium compounds”, an initiative of the Agencia Gallega de Innovación (GAIN) to facilitate the access of I+D+i projects to the market (J.L.M and B.S.,Jr.), a La Caixa Research Consolidate grant (CC21-20122; J.L.M and B.S.,Jr.); Spanish national grants PID2019-110320RB-I00 (M.A.F.-M.) from the Ministerio de Ciencia e Innovación (MCIN), IJC2019-040358-I funded by MCIN/AEI/10.13039/501100011033 (J.R.), PID2019-108624RB-I00, PDC2021-121508-I00, PID2022-137318OB-I00 and ORFEO-CINQA network RED2018-102387-T (J.L.M.), the Consellería de Cultura, Educación e Ordenación Universitaria 2015-CP082, IN855A 2018/16, ED431C-2021/25 and Centro Singular de Investigación de Galicia accreditation 2019-2022: ED431G 2019/03 (J.L.M.), the European Union (European Regional Development Fund-ERDF corresponding to the multiannual financial framework 2014-2020), and the European Research Council Advanced Grant No. 340055, Proof-of-concept Grant No. 899334 (J.L.M.). a Max Eder Fellowship of the German Cancer Aid (111746) (P.C.H.); the German Research Foundation (DFG, CRC 1279 “Exploiting the human peptidome for Novel Antimicrobial and Anticancer Agents”) (P.C.H.)., Peer reviewed